Internal Commitments, Out-Licensing Opportunities, and Discovery (NCE) Pipeline
BB106
Ketamine
Acute Pain Management
Mental Health Indications
BB206
Flumazenil
Benzodiazepine Addiction
BB605
Naloxone (Continuous Delivery)
Opioid Overdose
Bexson has validated SeValent™ technology with a broad range of existing molecules across several therapeutic areas. These include, but are not limited to:
Dalbavancin
Telavancin
Eravacycline
Tigecycline
Lefamulin
Amikacin
Caspofungin
DMT / Dimethyltryptamine
5-MeO-DMT
4-AcO-DIPT
Mescaline
2-CB
3-FMA
5-MAPB
3-MMC
5-IAI
Lidocaine
Bupivacaine
Ropivacaine
Morphine
Naloxone
Sumatriptan
Eletriptan
Naratriptan
Rizatriptan
Amifampridine
Pramipexole
Ropinirole
Levodopa/Carbidopa Prodrugs
Dextromethorphan
DCK / Deschloroketamine
D2FK / Deschloro-2-Fluoro-Ketamine
To Be Announced
To Be Announced
Bexson's science team is uniquely suited to develop New Chemical Entities targeting the NMDA receptor. We have established a new family of NMDA receptor antagonists with novel receptor binding profiles.